Dear Valued Customers and Partners,

As we approach the close of this year, we at ExSyn would like to extend our heartfelt gratitude for your trust, collaboration, and continued support. Your confidence in our products and services has been the driving force behind our growth and success.

The relationships we have built with you are at the core of everything we do, and we deeply appreciate the opportunity to serve and work alongside you. Looking ahead to the new year, we are excited to strengthen these bonds further, explore new opportunities together, and continue delivering value that supports your goals.

Thank you once again for being an integral part of our journey.

We wish you and your teams a prosperous, healthy, and fulfilling year ahead!

Warm regards,

The ExSyn Team

READ MORE
Exim rebrands as ExSyn: We celebrate our 30-year heritage with a new brand and website that bring alive our values and purpose
News · 27/03/2021

Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.

In focus: N,N′-Dimethylethylenediamine   
Products in focus · 10/11/2026

N,N′-Dimethylethylenediamine (DMEDA) is an organic chemical compound belonging to the diamine family. It contains two nitrogen atoms, each bearing a methyl group, connected by a two-carbon chain.

Global Freight Costs Surge 130%
News · 03/11/2026

Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.

FDA Issues Final Guidance on Manufacturing Changes for Biosimilars
News · 03/11/2026

The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.